Jade Biosciences (JBIO) Stock Price, News & Analysis

Company Overview

Jade Biosciences, Inc. (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates. As an early-stage biotechnology company, its programs remain subject to development, regulatory and clinical risks, and the timing of potential product launches is uncertain.

Key Stats

• Today's Range: $14.08 to $14.71
• 50-Day Range: $14.35 to $24.71
• 52-Week Range: $8.16 to $28.00
• Volume: 598,627 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $912.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.75
• Consensus Rating: Moderate Buy

Jade Biosciences Stock Analysis - MarketRank™

Jade Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 663rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Jade Biosciences has a consensus price target of $51.75, representing about 260.6% upside from its current price of $14.35.

Amount of Analyst Coverage

Jade Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jade Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.11) per share.

Price to Book Value per Share Ratio

Jade Biosciences has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.45% of the float of Jade Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Jade Biosciences has a short interest ratio ("days to cover") of 11.76, which indicates bearish sentiment.

Change versus previous month

Short interest in Jade Biosciences has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jade Biosciences does not currently pay a dividend.

Dividend Growth

Jade Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.44

News Sentiment

Jade Biosciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Jade Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for JBIO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Jade Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:JBIO
• Previous Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: www.jadebiosciences.com
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 55
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jade Biosciences: $51.75
• High Price Target: $77.00
• Low Price Target: $40.00
• Potential Upside/Downside: +260.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.11%
• Return on Assets: -45.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.93
• Quick Ratio: 14.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.74 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 63,600,000
• Free Float: 48,932,000
• Market Cap: $912.66 million
• Optionable: N/A
• Beta: 1.45